Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02047513
Other study ID # AIO-PAK-0313
Secondary ID 2013-005559-34AX
Status Completed
Phase Phase 2
First received
Last updated
Start date July 2015
Est. completion date October 2022

Study information

Verified date June 2023
Source AIO-Studien-gGmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

NEONAX is an interventional, prospective, randomized, controlled, open label, two sided survival phase II studies against a fixed survival probability, with an unconnected analysis of the results in both experimental arms. Determining the impact of 2 cycles of Perioperative nab-paclitaxel/gemcitabine followed by surgery and 4 cycles of adjuvant nab-paclitaxel/gemcitabine or 6 cycles of adjuvant nab-paclitaxel/gemcitabine on the Disease free survival (DFS) rate at 18 months post randomization


Description:

The planned trial will enable us to address the following issues: - Identification of patients who benefit from surgery. Tumor progress during intensified Perioperative chemotherapy is likely to indicate a particularly poor prognosis suggesting that these patients would not have benefitted from immediate surgery. - Assess tumor response/downsizing using nab-paclitaxel/gemcitabine also at the molecular level - Can we achieve a better systemic tumor control or reduce the metastatic spread using nab-paclitaxel/gemcitabine compared to adjuvant gemcitabine - Examining the effect of a more efficacious chemotherapy regimen (nab-paclitaxel/gemcitabine) in the adjuvant setting - Defining the impact of a perioperative or adjuvant chemotherapy with gemcitabine/nab-paclitaxel on DFS and 3-year Overall survival (OS) Histopathological tumor regression will be evaluated in addition to tumor size measurement according to Response Evaluation Criteria In Solid Tumors (RECIST). We will establish a histopathological tumor regression score to evaluate the efficacy of the neoadjuvant treatment. For this score we will examine tumor core biopsies obtained prior to neoadjuvant treatment and histological tumor specimen after surgery in both arms. To reliably determine R0 resections, the resected specimen will be prepared for pathology in a defined manner according to the procedure set out in the German S3 guidelines for pancreatic cancer. This trial provides the unique opportunity in pancreatic cancer to obtain material prior to and after surgery for biomarker analysis and correlation with outcome. We will perform pharmacogenomic candidate gene analysis of hENT1 (human equilibrative nucleoside transporter-1), CDA (cell differentiation agent), DCK (Desoxycytidin-Kinase) and 5´nucleotidase in both arms.


Recruitment information / eligibility

Status Completed
Enrollment 127
Est. completion date October 2022
Est. primary completion date April 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Histologically or cytological confirmed, clearly resectable ductal adenocarcinoma of the pancreas (PDAC) = cT3 with no prior tumor specific treatment. - No evidence of metastases to distant organs (e.g. liver, peritoneum, lung). - Resectable tumor. Determination of resectability based on spiral CT scans with both oral and i.v. contrast enhancement or on MRI using a recent consensus definition (Resectability: Clear fat planes around the celiac artery, hepatic artery and superior mesenteric artery.) - Measurable tumor according to RECIST 1.1 - ECOG performance status 0 or 1 - Creatinine clearance = 30 ml/min - Serum total bilirubin level = 2.5 x ULN (not necessary for enrollment or randomization, but before start of neoadjuvant chemotherapy in arm A) - ALT and AST = 2.5 x ULN (not necessary for enrollment or randomization, but before start of neoadjuvant chemotherapy in arm A) - In case of biliary obstruction, biliary decompression is required if the patient was randomized to receive neoadjuvant chemotherapy (arm A) - White blood cell count = 3.5 x 106/ml, neutrophil granulocytes count = 1,5 x 106/ml, platelet count = 100 x 106/ml - Signed informed consent incl. participation in translational research - Age = 18 years Exclusion criteria: - Borderline resectable PDAC by radiologic criteria - Papillary cancer - Neuroendocrine Cancer - Tumor specific pre-treatment - Local recurrence - Peritoneal or other distant metastases - Radiographic evidence of severe portal hypertension/cavernous transformation - Infiltration of extrapancreatic organs (except duodenum) - Ascites - Gastric outlet obstruction - Global respiratory insufficiency requiring oxygen supplementation - Chronic infectious diseases, immune deficiency syndromes - Premalignant hematologic disorders, e.g. myelodysplastic syndrome - Disability to understand and sign written informed consent document - Past or current history of malignancies except for the indication under this study and curatively treated: - Basal and squamous cell carcinoma of the skin - In-situ carcinoma of the cervix - Other malignant disease without recurrence after at least 2 years of follow-up - Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrollment - Clinically relevant or history of interstitial lung disease, e.g. non-infectious pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan or chest x-ray. - History of or evidence upon physical examination of CNS disease unless adequately treated (e.g. primary brain tumor, seizure not controlled with standard medical therapy or history of stroke). - Pre-existing neuropathy > grade 1 (NCI CTCAE) - Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy - Severe non-healing wounds, ulcers or bone fractions - Evidence of bleeding diathesis or coagulopathy - Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and PTT < 1.5 ULN within 28 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) - Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of pancreatic cancer with curative intent and central intravenous line placement for chemotherapy administration. - Pregnancy or breastfeeding women. - Subjects with known allergies to the study drugs or to any of its excipients. - Current or recent (within the 28 days prior randomization) treatment with another investigational drug or participation in another investigational study. - Any psychological, familial, sociological or geographical condition potentially compromising compliance with the study protocol and the follow-up schedule; those conditions should be discussed with the patient prior to registration in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
perioperative nab-paclitaxel/gemcitabine
2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
adjuvant nab-paclitaxel/gemcitabine
Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)

Locations

Country Name City State
Germany University of Ulm, Dept. of Internal Medicine I Ulm

Sponsors (3)

Lead Sponsor Collaborator
AIO-Studien-gGmbH Celgene, ClinAssess GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Disease free survival (DFS) To improve the DFS rate at 18 months in at least one arm to= 55% 18 months after randomization
Secondary Safety • Safety of nab-paclitaxel/gemcitabine in the neoadjuvant and adjuvant setting 57 months
Secondary morbidity and mortality • pre- and postoperative morbidity and mortality in both studies 7 years
Secondary toxicity • Dropout rate due to toxicity in the neoadjuvant study 57 months
Secondary Disease progression • Disease progression during neoadjuvant therapy 7 years
Secondary resection rate • R0 and R1 resection rate in both groups as assessed according to the German S3 guidelines 53 months
Secondary Tumor response • Tumor response according to RECIST v1.1; histopathological regression based on a predefined pathological handling of the resected specimen in the perioperative study 57 months
Secondary Correlation of tumor regression and R0 resection • Correlation of tumor regression and R0 resection rate with response according to RECIST v1.1 in the perioperative study 57 months
Secondary Overall survival • Overall survival in both studies 7 years
Secondary tumor recurrence • First site of tumor recurrence in both studies 7 years
Secondary quality of life • Explorative analysis of health related quality of life in both studies 57 months
Secondary pharmacogenomic markers, tumor-biomarkers and molecular analyses • Correlation of DFS, OS and tumor regression with pharmacogenomic markers, tumor-biomarkers and molecular analyses in both studies 57 months
Secondary Safety • Assessment of safety 57 months
Secondary Tumor response To assess tumor response using the imaging data (CT scans, MRI-scans) obtained during the trial 66 months
Secondary Tumor recurrence To assess tumor recurrence using the imaging data (CT scans, MRI-scans) obtained during the trial 66 months
See also
  Status Clinical Trial Phase
Recruiting NCT05209074 - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Phase 1
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Recruiting NCT02243007 - Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT05679050 - Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Withdrawn NCT01694589 - A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer Phase 0
Active, not recruiting NCT03138720 - Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Phase 2
Completed NCT01298011 - Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer Phase 2
Completed NCT06363084 - A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Recruiting NCT04810910 - Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Phase 1
Completed NCT01992705 - Borderline Pancreas Study: FOLFIRINOX +SBRT Early Phase 1
Recruiting NCT05624918 - A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma Phase 2
Completed NCT02115022 - EUS vs. MDCT in Pancreatic Malignancy
Recruiting NCT03492671 - Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer Phase 2
Terminated NCT05546411 - A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer Phase 2
Not yet recruiting NCT06172036 - Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab Phase 2
Recruiting NCT05788744 - Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer N/A
Recruiting NCT04737551 - Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
Recruiting NCT03822936 - Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma Phase 2
Completed NCT03435536 - Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer N/A